...ELN 2022 (0.640) and Beat AML 2024 (0.635) over ELN 2024 (0.601). For patients treated with IC, ELN 2022 (0.680) and Bea...
...ELNs (PELNs) in anti-CRC therapy. PELNs were successfully extracted via the ultra-centrifugation method and were effecti...
...ELN-defined low and high-risk disease; the ELN suggested criteria for using rIFNα in low-risk patients if certain issues...
...ELN), use cytogenetic and molecular markers to guide treatment decisions, their predictive accuracy remains suboptimal, ...
...ELN, TNMD), suggesting active matrix synthesis, while post-pubescent ACLs showed elevated secondary matrix genes (COL3A1...
...ELN) 2017 risk stratification, 52% of patients were categorized as favourable risk, 18% as intermediate risk and 28% as ...
...ELNs modulated the expression of multiple genes associated with oncogenic pathways, and miRNAs enriched in the ELNs play...
...ELNs by B16-F10 cells. Cell counting kit-8 assays indicated that N-ELNs exhibited no cytotoxic effects on melanoma cells...
...ELN 2022 guidelines.
...ELN) genes. The OC was thinner than the IC in both TAV and BAV (p < 0.001), with no regional differences in HTx. TAV dem...
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话: 0531-88819269